A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects
Cancer Chemotherapy and Pharmacology, 2021, 87, 349-359
This is an overview of where and by who this paper has been cited.
Help Us
Non-profit projects normally ask for donations. We don't. We will survive one way or another. If you wish to help us, please spread the word to let more people use this service.
It is delightful to see our efforts are useful to a broad range of researchers.
